Theralase® Technologies Inc. announced that its Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”) (Interim) data has been accepted by the American Society of Clinical Oncology (“ASCO”) Genito Urinary (“GU”) Cancer Symposium for a moderated poster presentation. The GU-ASCO cancer symposium will take place between February 16th to 18th, 2023 in San Francisco, California with the poster presented for general viewing and discussion within Poster Session B: Prostate Cancer and Urothelial Carcinoma on February 17, 2023 at 12:30 PM to 2:00 PM and 5:15 PM to 6:15 PM. The poster titled: “A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC (interim analysis)” will be presented by the lead author, Girish Kulkarni M.D., Ph.D., FRCSC, Divisions of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Professor, University of Toronto, (Toronto, Ontario, Canada).

The poster will include interim clinical data and analysis collected through the enrollment and treatment of patients at all Canadian and US clinical study site by their respective principal investigators for Study II.